Georgios Tsakonas

Publikationer
CV
Populärvetenskap och samverkan

Artiklar

Article: EUROPEAN JOURNAL OF RADIOLOGY. 2024;177:111557
Diffusion weighted MRI and apparent diffusion coefficient as a prognostic biomarker in evaluating chemotherapy-antiangiogenic treated stage IV non-small cell lung cancer: A prospective, single-arm, open-label, clinical trial (BevMar)
Grundberg O; Skribek M; Swerkersson S; Skorpil M; Kolbeck K; Grozman V; Nyren S; Tsakonas G
Article: ESMO OPEN. 2023;8(6):102069
Validation of the ALK-Brain Prognostic Index for patients with ALK- rearranged lung cancer and brain metastases
Zerdes I; Kamali C; Koulouris A; Elsayed M; Schnorbach J; Christopoulos P; Tsakonas G
Article: LUNG CANCER. 2023;182:107292
Cerebrospinal fluid as a liquid biopsy for molecular characterization of brain metastasis in patients with non-small cell lung cancer
Tsakonas G; Tadigotla V; Chakrabortty SK; Stragliotto G; Chan D; Lewensohn R; Yu W; Skog JK; Hydbring P; Ekman S
Article: PLOS ONE. 2023;18(2):e0277708
Effect of body tissue composition on the outcome of patients with metastatic non-small cell lung cancer treated with PD-1/PD-L1 inhibitors
Makrakis D; Rounis K; Tsigkas A-P; Georgiou A; Galanakis N; Tsakonas G; Ekman S; Papadaki C; Monastirioti A; Kontogianni M; Gioulbasanis I; Mavroudis D; Agelaki S
Article: INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2022;24(1):193
Matched Analyses of Brain Metastases versus Primary Non-Small Cell Lung Cancer Reveal a Unique microRNA Signature
Tsakonas G; Koulouris A; Kazmierczak D; Botling J; Ortiz-Villalon C; Nord H; Lindskog M; Sandelin M; Micke P; Hydbring P; Ekman S
Article: TRANSLATIONAL LUNG CANCER RESEARCH. 2022;11(10):2064-2078
Plasma RNA profiling unveils transcriptional signatures associated with resistance to osimertinib in EGFR T790M positive non-small cell lung cancer patients
Alexeyenko A; Brustugun OT; Eide IJZ; Gencheva R; Kosibaty Z; Lai Y; de Petris L; Tsakonas G; Grundberg O; Franzen B; Viktorsson K; Lewensohn R; Hydbring P; Ekman S
Article: CANCERS. 2022;14(14):3430
Ras-Related Protein Rab-32 and Thrombospondin 1 Confer Resistance to the EGFR Tyrosine Kinase Inhibitor Osimertinib by Activating Focal Adhesion Kinase in Non-Small Cell Lung Cancer
Kosibaty Z; Brustugun OT; Eide IJZ; Tsakonas G; Grundberg O; De Petris L; McGowan M; Hydbring P; Ekman S
Article: TRANSLATIONAL LUNG CANCER RESEARCH. 2022;11(5):722-734
Elevated expression of miR-494-3p is associated with resistance to osimertinib in EGFR T790M-positive non-small cell lung cancer
Kazmierczak D; Eide IJZ; Gencheva R; Lai Y; Lewensohn R; Tsakonas G; Grundberg O; de Petris L; McGowan M; Brustugun OT; Ekman S; Hydbring P
Article: LUNG CANCER. 2022;166:49-57
Patient-reported health-related quality of life from a randomized phase II trial comparing standard-dose with high-dose twice daily thoracic radiotherapy in limited stage small-cell lung cancer
Killingberg KT; Halvorsen TO; Flotten O; Brustugun OT; Langer SW; Nyman J; Hornslien K; Madebo T; Schytte T; Risum S; Tsakonas G; Engleson J; Gronberg BH
Article: LUNG CANCER. 2022;166:132-134
Osimertinib-induced syndrome of inappropriate secretion of antidiuretic hormone in oncogene-addicted lung adenocarcinoma: A case report
Skribek M; Bozoky B; Tsakonas G
Article: CANCERS. 2021;13(13):3151
High Density of NRF2 Expression in Malignant Cells Is Associated with Increased Risk of CNS Metastasis in Early-Stage NSCLC
Tsakonas G; Martin-Bernabe A; Rounis K; Moreno-Ruiz P; Botling J; De Petris L; Ylipaa A; Mezheyeuski A; Micke P; Ostman A; Ekman S
Article: ACTA ONCOLOGICA. 2021;60(3):305-311
Extending hypofractionated stereotactic body radiotherapy to tumours larger than 70cc-effects and side effects
Grozman V; Onjukka E; Wersall P; Lax I; Tsakonas G; Nyren S; Lewensohn R; Lindberg K
Article: CANCERS. 2021;13(7):1562
Correlation of Clinical Parameters with Intracranial Outcome in Non-Small Cell Lung Cancer Patients with Brain Metastases Treated with Pd-1/Pd-L1 Inhibitors as Monotherapy
Rounis K; Skribek M; Makrakis D; De Petris L; Agelaki S; Ekman S; Tsakonas G
Article: EUROPEAN JOURNAL OF CANCER. 2021;145:245-254
Effect of corticosteroids on the outcome of patients with advanced non-small cell lung cancer treated with immune-checkpoint inhibitors
Skribek M; Rounis K; Afshar S; Grundberg O; Friesland S; Tsakonas G; Ekman S; De Petris L
Article: LANCET ONCOLOGY. 2021;22(3):321-331
High-dose versus standard-dose twice-daily thoracic radiotherapy for patients with limited stage small-cell lung cancer: an open-label, randomised, phase 2 trial
Gronberg BH; Killingberg KT; Flotten O; Brustugun OT; Hornslien K; Madebo T; Langer SW; Schytte T; Nyman J; Risum S; Tsakonas G; Engleson J; Halvorsen TO
Article: CANCERS. 2020;12(12):E3707-3707
Outcome of Patients with NSCLC and Brain Metastases Treated with Immune Checkpoint Inhibitors in a 'Real-Life' Setting
Skribek M; Rounis K; Makrakis D; Agelaki S; Mavroudis D; De Petris L; Ekman S; Tsakonas G
Article: CLINICAL LUNG CANCER. 2020;21(6):e544-e546
Primary CNS Metastatic BRAF-mutated Lung Adenocarcinoma With Complete Intracranial Response to BRAF/MEK Inhibition
Tsakonas G; Grozman V; Ekman S
Article: CANCERS. 2020;12(11):E3110-3110
Randomized Phase II Study with Cetuximab in Combination with 5-FU and Cisplatin or Carboplatin Vs. Cetuximab in Combination with Paclitaxel and Carboplatin for Treatment of Patients with Relapsed or Metastatic Squamous Cell Carcinoma of the Head and Neck (CETMET Trial)
Tsakonas G; Specht L; Kristensen CA; Moreno MHC; Haugen Cange H; Soderstrom K; Friesland S
Article: CANCERS. 2020;12(7):E1804-1804
ALK-Brain Prognostic Index-Preliminary Study of a Prognostic Tool for Patients with ALK-Rearranged, Non-small Cell Lung Cancer and Brain Metastases
Tsakonas G; Kamali C; De Petris L; Friesland S; Lewensohn R; Ekman S
Article: EUROPEAN JOURNAL OF CANCER. 2020;132:24-34
An immune gene expression signature distinguishes central nervous system metastases from primary tumours in non-small-cell lung cancer
Tsakonas G; Lewensohn R; Botling J; Ortiz-Villalon C; Micke P; Friesland S; Nord H; Lindskog M; Sandelin M; Hydbring P; Ekman S
Article: LUNG CANCER. 2019;133:69-74
c-MET as a biomarker in patients with surgically resected non-small cell lung cancer
Tsakonas G; Botling J; Micke P; Rivard C; LaFleur L; Mattsson J; Boyle T; Hirsch FR; Ekman S
Article: LUNG CANCER. 2018;120:75-81
Validation of the 8th TNM classification for small-cell lung cancer in a retrospective material from Sweden
Tendler S; Grozman V; Lewensohn R; Tsakonas G; Viktorsson K; De Petris L
Article: ACTA ONCOLOGICA. 2018;57(2):231-238
Prognostic factors affecting survival after whole brain radiotherapy in patients with brain metastasized lung cancer
Tsakonas G; Hellman F; Gubanski M; Friesland S; Tendler S; Lewensohn R; Ekman S; de Petris L
Article: TUMOR BIOLOGY. 2014;35(5):4479-4488
PTPN6 expression is epigenetically regulated and influences survival and response to chemotherapy in high-grade gliomas.
Sooman L; Ekman S; Tsakonas G; Jaiswal A; Navani S; Edqvist P-H; Pontén F; Bergström S; Johansson M; Wu X; Blomquist E; Bergqvist M; Gullbo J; Lennartsson J
Article: INTERNATIONAL JOURNAL OF CANCER. 2014;134(7):1751-1757
Cancer incidence and mortality patterns in women with anorexia nervosa
Karamanis G; Skalkidou A; Tsakonas G; Brandt L; Ekbom A; Ekselius L; Papadopoulos FC
Article: MEDICAL ONCOLOGY. 2013;30(3):638
Vandetanib combined with a p38 MAPK inhibitor synergistically reduces glioblastoma cell survival.
Sooman L; Lennartsson J; Gullbo J; Bergqvist M; Tsakonas G; Johansson F; Edqvist P-H; Pontén F; Jaiswal A; Navani S; Alafuzoff I; Popova S; Blomquist E; Ekman S
Visa fler

Alla övriga publikationer

Review: INTERNATIONAL JOURNAL OF CANCER. 2023;153(9):1556-1567
Safety and efficacy of immune checkpoint blockade in patients with advanced nonsmall cell lung cancer and brain metastasis
Tsakonas G; Ekman S; Koulouris A; Adderley H; Ackermann CJ; Califano R
Review: JOURNAL OF INTERNAL MEDICINE. 2022;291(6):732-754
Complications following novel therapies for non-small cell lung cancer
Skribek M; Rounis K; Tsakonas G; Ekman S
Review: CLINICAL RHEUMATOLOGY. 2021;40(5):1687-1695
Treatment of rheumatic immune-related adverse events due to cancer immunotherapy with immune checkpoint inhibitors-is it time for a paradigm shift?
Chatzidionysiou K; Liapi M; Tsakonas G; Gunnarsson I; Catrina A
Thesis / dissertation: 2020
Biomarkers for CNS metastasis in non-small cell lung cancer (NSCLC)
Tsakonas, Georgios
Review: EUROPEAN JOURNAL OF CANCER. 2020;125:1-11
Immune checkpoint blockade for non-small cell lung cancer: What is the role in the special populations?
Califano R; Gomes F; Ackermann CJ; Rafee S; Tsakonas G; Ekman S
Corrigendum: LUNG CANCER. 2018;123:178-179
Validation of the 8th TNM classification for small-cell lung cancer in a retrospective material from Sweden (vol 120, pg 75, 2018)
Tendler S; Grozman V; Lewensohn R; Tsakonas G; Viktorsson K; De Petris L
Review: JOURNAL OF THORACIC DISEASE. 2018;10(Suppl 13):S1547-S1555
Oncogene-addicted non-small cell lung cancer and immunotherapy
Tsakonas G; Ekman S
Review: CANCER TREATMENT REVIEWS. 2017;54:122-131
Management of brain metastasized non-small cell lung cancer (NSCLC) - From local treatment to new systemic therapies
Tsakonas G; De Petris L; Ekman S

Anställningar

Postdoktorala Studier, Onkologi-Patologi, Karolinska Institutet, 2023-2026

Examina och utbildning

Medicine Doktorsexamen, Institutionen för onkologi-patologi, Karolinska Institutet, 2020

Artiklar

Alla övriga publikationer

Anställningar

Examina och utbildning

Nyheter från KI

Kalenderhändelser från KI